alexa The Development of an At-Risk Biosensor for Cardiovascular Disease | OMICS International | Abstract
ISSN: 2090-4967

Biosensors Journal
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

The Development of an At-Risk Biosensor for Cardiovascular Disease

Sandra Ivonne Gonzalez1 and Jeffrey T. La Belle2*

1Department of Biomedical Engineering, College of Engineering, The University of Arizona, Tucson, AZ 85721, USA

2Harrington Biomedical Engineering Program, School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ 85287, USA

*Corresponding Author:
Jeffrey T. La Belle
E-mail: [email protected]

Received date: 27 July 2012; Revised date: 29 September 2012; Accepted date: 13 October 2012


Cardiovascular disease (CVD) is a leading cause of death worldwide. Several biomarkers have been found useful in diagnosis and management of CVD, so there is an enormous potential utility for a point-of-care biosensor capable of measuring the entire panel of CVD biomarkers on demand. This paper presents one potential component of such a biosensor, in the form of an electrochemical impedance spectroscopy (EIS)-based measurement method for one such CVD biomarker, neutrophil gelatinaseassociated lipocalin (NGAL). In this study, an antibodyfunctionalized gold disk electrode is shown to detect NGAL in blood diluted to 10% concentration, with a slope of 5.6824 ohms/LOG (ng/mL) and an R2 of 0.97 (n = 3) at 1.758 kHz. These results show the feasibility of an EISbased point-of-care biosensor for CVD markers. Future work will include expanding the method demonstrated here to cover other CVD biomarkers and integrating multiple markers into a single sensor device.